Susceptibility of clinical Candida species isolates to antifungal agents by E-test, Southern Iran: A five year study

Badiee P*, Alborzi A

Prof. Alborzi Microbiology Research Center, Mycology Department, Shiraz University of Medical Sciences, Shiraz, Iran.

Received: September 2011, Accepted: November 2011.

ABSTRACT

Background and Objectives: The incidence of fungal infections in immunocompromised patients, especially by Candida species, has increased in recent years. This study was designed to identify Candida species and determine antifungal susceptibility patterns of 595 yeast strains isolated from various clinical specimens.

Material and Methods: Identification of the isolates were determined by the API 20 C AUX kit and antifungal susceptibilities of the species to fluconazole, amphotericin B, ketoconazole, itraconazole, voriconazole, and caspofungin were determined by the agar-based E-test method.

Results: Candida albicans (48%) was the most frequently isolated species, followed by Candida kruzei (16.1%), Candida glabrata (13.5%), Candida kefyr (7.4%), Candida parapsilosis (4.8%), Candida tropicalis (1.7%) and other species (8.5%). Resistance varies depending on the species and the respective antifungal agents. Comparing the MIC90 for all the strains, the lower MIC90 was observed for caspofungin (0.5 µg/ml). The MIC90 for all Candida species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazole, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.

Conclusions: Species definition and determination of antifungal susceptibility patterns are advised for the proper management and treatment of patients at risk for systemic candidiasis. Resistance to antifungal agents is an alarming sign for the emerging common nosocomial fungal infections.

Keywords: Candida, amphotericin B, itraconazole, voriconazole, antifungal susceptibility, E-test

INTRODUCTION

Systemic candidiasis (SC) is the most common invasive fungal infection as the nosocomial infection in patients undergoing major surgeries during prolonged neutropenia, transplantation and extended hospital stays of days to weeks, (1), (2). This infection is potentially a life-threatening complication in immunocompromised patients. The introduction of novel antineoplastic agents, antifungals, antibacterial and antivirals over the past 10 years has led to a shift in fungal epidemiology (2, 3) and fever without specific signs and symptoms of localized fungal infection is the most common clinical presentation. Intensive and long-term use of antifungals leads to a decline in sensitivity and resistance development of Candida strains (4). Antifungal resistance surveillance serves as a major strategy for prophylaxis, empirical therapy, and treatment of SC. For the management of patients suffering from SC, determination of the changes in the distribution of Candida species and respective sensitivity pattern to antifungal agents are important.

Antifungal prophylaxis is warranted in patients with developing risk of SC. As definitive early diagnosis is difficult, empiric therapy of antifungal agents has become a standard of practice in immune-suppressed patients like neutropenic patients who had received
broad spectrum antibacterial therapy but remain persistently febrile. The antifungal susceptibility testing of pathogenic fungi can manage the selection of adequate therapy and also provide an estimate of antifungal efficacy. Monitoring of drug resistance development can predict therapeutic outcome and therapeutic potential of untested compounds (5-7).

The purpose of this study was to determine the distribution of Candida species and in vitro susceptibilities of antifungal agents against the Candida isolated from the patients referred to a mycology center in southern Iran using E-test for the best management and treatment of those at risk for SC.

MATERIALS AND METHODS

This study was designed in mycology department, Clinical Microbiology Research Center, Shiraz University of Medical Sciences, southern Iran from October 2005 to October 2010. Clinical samples including mouth, blood, abdominal tap, urine, sputum, esophageal, oropharyngeal, vagina, biopsy and bronchoalveolar lavage of patients were cultured on sabouraud dextrose agar (Merck, Germany) and incubated at 24°C for 10 days. All Candida spp. isolated were cultured on potato dextrose agar (OXOID LTD, Basingstoke, Hampshire, England) twice for 48h at 35°C for the purity inspected. For species typing of the isolates, germ tube and chlamydomysopore production tests were performed. The carbohydrate assimilation patterns of all the isolates were studied using the API 20 C AUX system according to the manufacturer’s procedure (Biomerieux, France). Candida (C) dubliniensis sp. was recognized by molecular assay from Candida albicans (8) because these species have the same pattern for carbohydrate assimilation. Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 (9) were quality controls and tested each day for all antifungal agents.

Susceptibility test for the isolates was performed by the agar-based E-test method (Biomeriu, Sweden) with RPMI 1640, 8.4 gram per litter (RPMI; Sigma Chemical Co., St. Louis, Mo.), 2% glucose and 1.5% agar which buffered to PH 7.0 with 0.165 M morpholinepropanesulfonic acid buffer (Sigma, St. Louis, Mo.), poured in 90-mm-diameter plates. The plates were inoculated by dipping a sterile swab into the inoculum suspension adjusted to the turbidity of a 0.5 McFarland standard (10⁶ cells/ml) and streaking it across the surface of the agar in four directions. The plates were dried at ambient temperature for 15 minutes before applying the E-test strips. The MIC endpoints were determined after 24 and 48 h of incubation at 35°C. The MIC was read for amphotericin B, as the drug concentration that zone determined the point of complete inhibition (100%), and for ketoconazole; itraconazole, voriconazole and caspofungin the significant inhibition decreased 80% of the growth. The resistance breakpoints for antifungals are amphotericin B > 1.0; fluconazole ≥ 64; itraconazole ≥ 1.0; voriconazole ≥ 8.0; ketoconazole ≥ 4.0; and caspofungin ≥ 2.0 micrograms per milliliter (10-15). MIC50 and MIC90 (the MIC at which 50% and 90% of the isolates are inhibited) were also calculated.

Data were entered into SPSS version 16 and were subsequently analyzed using descriptive statistics and cross tabulation.

RESULTS

Totally, 595 Candida spp. were isolated from the
Table 2. Distributions of MIC (µg/ml) by E-test method:

| Species (no. isolates) | Antifungal agent | Range | 50% | 90% | Number of Resistance (%) |
|------------------------|------------------|-------|-----|-----|--------------------------|
| *C. albicans* (285)     | Fluconazole      | 1.00-64.0 | 4.00 | 16.00 | 30 (10.5%) |
|                        | Amphotericin     | 0.032-1.00 | 0.032 | 0.500 | 20 (7%) |
|                        | Ketoconazole     | 0.002-16.00 | 0.064 | 4.00 | 27 (9.4%) |
|                        | Itraconazole     | 0.016-4.00 | 0.190 | 2.00 | 96 (33.7%) |
|                        | Voriconazole     | 0.025-0.003-16.00 | 0.064 | 4.00 | 17 (6%) |
|                        | Caspofungin      | 1.00 | 0.025 | 0.075 | 5 (1.8%) |
| *C. krusei* (96)        | Fluconazole      | 4.00-64.00 | 8.00 | 128.00 | 64 (66.6%) |
|                        | Amphotericin     | 0.064-1.00 | 0.125 | 0.250 | 3 (3.1%) |
|                        | Ketoconazole     | 0.380-32.00 | 1.500 | 4.00 | 10 (10.4%) |
|                        | Itraconazole     | 0.500-16.00 | 0.500 | 4.00 | 83 (86.5%) |
|                        | Voriconazole     | 0.100-32.00 | 0.500 | 2.00 | 19 (19.8%) |
|                        | Caspofungin      | 0.015-0.5 | 0.24 | 0.500 | 4 (4.2%) |
| *C. glabrata* (80)      | Fluconazole      | 0.75-256 | 64.00 | 128.0 | 48 (60%) |
|                        | Amphotericin     | 0.013-1 | 0.190 | 0.500 | 2 (2.5%) |
|                        | Ketoconazole     | 0.013-12 | 1.500 | 6.00 | 12 (15%) |
| *C. Kefyr* (44)         | Itraconazole     | 0.500-16.00 | 2.00 | 16.00 | 68 (85%) |
|                        | Voriconazole     | 0.012-8.00 | 0.750 | 3.00 | 8 (10%) |
|                        | Caspofungin      | 0.03-4.00 | 0.06 | 0.12 | 3 (3.7%) |
| *C. parapsilosis* (29)  | Fluconazole      | 0.038-128.0 | 1.00 | 8.000 | 20 (45.5%) |
|                        | Amphotericin     | 0.016-1.00 | 0.190 | 0.750 | 2 (4.5%) |
|                        | Ketoconazole     | 0.012-0.190 | 0.032 | 0.047 | 1 (2.3%) |
|                        | Itraconazole     | 0.002-1.00 | 0.047 | 0.500 | 5 (11.4%) |
|                        | Voriconazole     | 0.008-16.00 | 0.023 | 0.064 | 1 (2.3%) |
|                        | Caspofungin      | 0.03-1 | 0.064 | 0.125 | 1 (2.3%) |
| *C. parapsilosis* (29)  | Fluconazole      | 2.00-64.00 | 1.00 | 4.000 | 2 (6.9%) |
|                        | Amphotericin     | 0.023-0.500 | 0.250 | 0.500 | 1 (3.5%) |
|                        | Ketoconazole     | 0.016-0.064 | 0.023 | 0.047 | 1 (3.5%) |
|                        | Itraconazole     | 0.023-0.500 | 0.125 | 0.250 | 1 (3.5%) |
|                        | Voriconazole     | 0.006-0.047 | 0.016 | 0.032 | 0.00 |
|                        | Caspofungin      | 0.03-2 | 0.25 | 1.00 | 0.00 |

Resistance is defined as the following MIC in micrograms per milliliter: Flu ≥ 64; AMB > 1.0; Keto ≥ 4.0; Itra ≥ 1.0; Vori ≥ 4.0; and Caspofungin ≥ 2.0.

patients. The most sites of the isolated (70%) were mouth and lung (sputum and bronchoalveolar lavage), but *Candida* species were also isolated from the blood, cerebro spinal fluid, sinus biopsy, eyes, pleural and abdominal tap. The most species isolated from the patients was *C. albicans* followed by *C. krusei*, *C. glabrata*, *C. kefyr*, and *C. parapsilosis* (Table 1).

*Candida albicans*, the most species isolated, was
sensitive to caspofungin, voriconazole, amphotericine B, ketoconazone, and fluconazole with 98.2%, 94%, 93%, 90.6%, and 89.5%, respectively. Of the 96 C. krusei strains, 32 (33.4%) were sensitive to fluconazole, 93 (96.9%) to amphotericine B, 86 (89.6%) to ketoconazone, 77 (80.2%) to voriconazole and 92 (95.8%) to caspofungin. Among the 80 C. glabrata, the third isolated species, 32 (40%) were found to be sensitive to fluconazole, 78 (97.5%) to amphotericine B, 68 (85%) to ketoconazone, 72 (90%) to voriconazole and 77 (96.3%) to caspofungin. Candida kefyr species had the least sensitivity to fluconazole 24 (54.5%), and high sensitivity (> 85%) to the other antifungals. Candida Parapsilopsis species showed high sensitivity rate to all antifungal agents. The lowest sensitivity was seen to itraconazole, C. albicans 189 (66.3%), C. glabrata 12 (15%), and C. krusei 13 (13.5%). Table 2 presents the antifungal susceptibility testing of Candida isolates to antifungal agents by E-test.

Comparing the MIC90 of species, the lowest MIC90 was observed for caspofungin (0.5 µg/ml). The MIC90 for all Candida species were 64 µg/ml for fluconazole, 0.75 µg/ml for amphotericin B, 4 µg/ml for ketoconazone, 4 µg/ml for itraconazole, and 2 µg/ml for voriconazole.

DISCUSSION

In the present study, the agar-based E-test was used and performed well for the testing of antifungal agents as there are reports about the usefulness of this method and agreement between the E-test and the broth micro-dilution MIC for Candida species and different types of antifungal agents (16, 17).

In this study, we isolated 595 strains from various clinical samples with higher rate of C. albicans (48%), followed by C. glabrata (13.5%) and C. Parapsilopsis (4.8%) (Table 1). The distributions of the species are different in various regions and studies, like 50% C. albicans, 24.7% C. glabrata, and 1% C. parapsilosis in other studies (18, 19). These observations establish the great importance of non-albicans Candida as a pathogen in clinical samples. It is important that increase in non-albicans species in SC with intensive and long-term use of antifungals leads to higher level of resistance of Candida strains to the antifungal drugs (20-22). A remarkable point in our study is that the most commonly isolated species was C. albicans in the clinical samples followed by C. krusei and C. glabrata which can pose a serious threat due to resistance to the routine antifungal agents.

Amphotericin B deoxycholate was the first systemic antifungal agent for the treatment of invasive fungal infections and has been the drug of choice (23, 24), however, due to nephrotoxicity in up to 80% of the patients, use of amphotericin B has been limited (25). Specific breakpoint for amphotericin B has not been proposed because it can positively affect the immune system and stimulates the body defenses against fungal infections (26, 27); therefore, the correlation between in vitro susceptibility pattern and in vivo responses in patients is not predictable. Resistance to amphotericin B as a routine antifungal agent and valid in our hospital for SC, varies in different studies. All Candida isolates in Tseng et al. 2005, were susceptible to amphotericin (17) but in our study 7% of C. albicans with MIC90, 0.500 µg/ml, 3.1% of C. krusei (MIC90 0.250 µg/ml), and 2.5% of C. glabrata (MIC90 0.500 µg/ml) were resistant to it.

Development of the triazoles in the 1990s provided alternative options for treating SC. Long-term fluconazole and itraconazole prophylaxis was associated with reduction in susceptibility to these agents. Susceptibility of C. albicans to fluconazole in this study was 89.5% (at MIC ≤ 16 µg/mL), comparable with the susceptibility rates reported in other studies (80.9%, 87%, 79% and 87.5%) (17, 28-30). The resistant rate of C. albicans to itraconazole in this study was 33.7%, and MIC90% for it was presented ≤ 6 µg/ml. Different rates of resistance to fluconazole and itraconazole were detected in Candida strains especially non albicans strain (14, 18). From the standpoint of antifungal resistance, C. glabrata and C. krusei are clearly the Candida species with the greatest potential to acquire resistance to fluconazole and other azoles (14, 15). Of the 96 C. krusei strains, 83 (86.3%) were resistant to itraconazole, 64 (66.6%) to fluconazole, 19 (19.8%) to voriconazole, 4 (4.2%) to caspofungin, and 3 (3.1%) to amphotericine B. Also, the MIC of C. glabrata was higher than that for all other species of Candida to triazoles agents (Table 2).

Blood stream infection due to C. kefyr is uncommon, but there has been some reports in immunocompromised patients (31) and resistance to antifungals in the literature (4, 20). In the present study, 7.4% of Candida isolates were C. kefyr, of which 45.5% were resistant to fluconazole but sensitive to the other antifungals.
There were many species which resisted two or three azole antifungal agents and with higher MIC for other azole antifungal agents. This shows that the resistance to one azole can lead to resistance to other azoles, as reported in other studies (14, 15) and thus, is a caution for use of this agent in clinical practice.

Caspofungin is the first echinocandin, approved in 2002 with the mechanism of inhibiting the 1, 3-β d-glucan as an integral part of the fungal cell wall. In the present study, caspofungin was the most active compound inhibiting 90% of C. albicans isolates at 0.075 µg/ml, C. kruusei in 0.5 µg/ml, C. glabrata in 0.12 µg/ml; C. Kefyr in 0.125 µg/ml; and C. parapsilosis in 1.0 µg/ml. Some species such as C. parapsilosis and C. guilliermondii have a relatively higher echinocandin MIC (32).

There are many view points on the use of new antifungal agents. Such agents are very effective but in many countries, especially in the developing ones, they are very expensive or not available to the respective patients. Therefore, we need to know the antifungal susceptibility rates in each region for the available agents in order to better manage the patients.

The successful treatment of SC depends on the early identification of the species and sensitivity patterns to antifungal agents. The high growing rate of non albicans Candida resistant to azole confirms the importance of monitoring changes in the distribution of pathogenic Candida species. The sensitivity pattern of Candida species as revealed in this study shows that amphotericin B, voriconazole, and caspofungin with the lowest MIC seem to be suitable drugs for empirical therapy and fluconazole and itraconazole are not suitable because of their high MIC and Candida species resistance to them.

ACKNOWLEDGEMENTS

We would like to thank Dr.M. Moein and M. Didari for their help with culture and drug concentration synthesis and Dr. H. Khajehei for copy editing of the manuscript.

REFERENCES

1. Badiee P, Alborzi A, Joukar M. Molecular assay to detect nosocomial fungal infections in intensive care units. Europ J Intern Med 2011; 22: 611-615.
2. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
3. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The hematologic epidemiology of fungal infections in patients with malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-1075.
4. Badiee P, Alborzi A, Shakiba E, Farshad S, Japoni A. Susceptibility of Candida species isolated from immunocompromised patients to antifungal agents. EMHJ 2011; 17: 425-430.
5. Comert F, Kulah C, Aktas E, Eroğlu O, Ozlu N. Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period. Mycoses 2007; 50: 52-57.
6. Pfaffer MA, Yu WL: Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am 2001; 15: 1227-1261.
7. Eraso E, Ruesga M, Villar-Vidal M, Carrillo-Muñoz AJ, Espinel-Ingroff A, et al. Comparative evaluation of ATB Fungus 2 and Sensititre Yeast One panels for testing in vitro Candida antifungal susceptibility. Rev Iberoam Microl 2008; 25: 3-6.
8. Mannarelly BM, Kurtzman CP: Rapid identification of Candida albicans and other human pathogenic yeast by using short oligonucleotides in a PCR. J Clin Microbiol 1998; 36: 1634-1641.
9. Messer SA, Diekema DJ, Boyken L, Tendolkar S, Hollis RJ, Pfaffer MA: Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006; 44: 324-326.
10. Pfaffer MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibility of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006; 44: 760-763.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts: Approved standard; 2nd ed. NCCLS Document M27-A2. Wayne, PA; 2002.
12. Blignaut E, Messer S, Hollis RJ, Pfaffer MA. Antifungal susceptibility of south African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis 2002; 44: 169-174.
13. Davey KG, Holmes AD, Johnson EM, Szekely A, Warnock DW: Comparative evaluation of FUNGITEST and broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. J Clin Microbiol 1998; 36: 926-930.
14. Swinnen D, Watelle M, Van der Flaes M, Nolard N: In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates. Mycoses 2004; 47: 177-183.
15. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015.
16. Pfaffer MA, Diekema DJ, Boyken L, Messer SA,
Tendolkar S, Hollis RJ. Evaluation of the E-test and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole. J Clin Microbiol 2003; 41: 1875-1880.

17. Teseng YH, Lee WT, Kuo TC. In-Vitro susceptibility of fluconazole and amphotericin B against Candida isolates from women with vaginal candidiasis in Taiwan. J Food Drug Analysis 2005; 13: 12-16.

18. Mimica LMJ, Ueda SMY, Martino MDV, Navarini A, Martini IJ. Candida infection diagnosis: evaluation of Candida species identification and characterization of susceptibility profile. J Bras Patol Med Lab 2009; 45: 17-23.

19. Ramani R, Chaturvedi V. Proficiency testing program for clinical laboratories performing antifungal susceptibility testing of pathogenic yeast species. J Clin Microbiol 2003; 41: 1143-1146.

20. Badiee P, Alborzi A, Davarpanah MA, Shakiba E. Distributions and antifungal susceptibility of Candida species from mucosal sites in HIV positive patients. Arch Iran Med 2010; 13: 282-287.

21. Berry V, Badyal DK. Sensitivity of clinical isolates of Candida species to antifungal drugs. J Med Education Res 2006; 8: 214-217.

22. Badiee P, Alborzi A, Shakiba E, Ziyaeyan M, Rasuli M. Molecular identification and in-vitro susceptibility of Candida albicans and Candida dubliniensis isolated from Immunocompromised patients. Iranian Red Cres Med J 2009; 11: 391-397.

23. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EGV, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.

24. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen S.H, Amphotericin B. Time for a new “gold standard”. Clin Infect Dis 2003; 37: 415-425.

25. Chen SC, Sorrell TC: Antifungal agents. Med J Aust 2007; 187: 404-409.

26. McGuire TR, Trickler WJ, Hock L, Vrana A, Hoie EB, Miller DW. Release of prostaglandin E-2 in bovine brain endothelial cells after exposure to three unique forms of the antifungal drug amphotericin-B: role of COX-2 in amphotericin-B induced fever. Life Sci 2003; 72: 2581-2590.

27. Lord AM, North TE, Zon LI, Prostaglandin E2, making more of your marrow. Cell Cycle 2007; 6: 3054-3057.

28. Saporiti AM, Gómez D, Levalle S, Galeano M, Davel G, Vivot W, et al. Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use. Rev Argent Microbiol 2001; 33: 217-222.

29. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 2002; 187: 569-574.

30. Citak S, Ozcelik B, Cesar S, Abbasoglu U. In vitro susceptibility of Candida isolated from blood culture to some antifungal agents. Jpn J Infect Dis 2005; 58: 44-46.

31. Reuter CW, Morgan MA, Bange FC, Gunzer F, Eder M, Hertenstein B, et al. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients. Clin Infect Dis 2005; 41: 1365-1366.

32. Bal AM. The echinocandins: three useful choices or three too many? Int J Antimicrob Agents 2010; 35: 13-18.